Search

Your search keyword '"Papadimitrakopoulou, Vali A"' showing total 24 results
Start Over Author "Papadimitrakopoulou, Vali A" Search Limiters Peer Reviewed
24 results on '"Papadimitrakopoulou, Vali A"'

1. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC

Author

Lin, Steven H., Lin, Yan, Yao, Luyang, Kalhor, Neda, Carter, Brett W., Altan, Mehmet, Blumenschein, George, Byers, Lauren A., Fossella, Frank, Gibbons, Don L., Kurie, Jonathan M., Lu, Charles, Simon, George, Skoulidis, Ferdinandos, Chang, Joe Y., Jeter, Melenda D., Liao, Zhongxing, Gomez, Daniel R., O’Reilly, Michael, Papadimitrakopoulou, Vali, Thall, Peter, Heymach, John V., and Tsao, Anne S.

Published
2020
Full Text
View/download PDF

4. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer

Author

Lissanu Deribe, Yonathan, Sun, Yuting, Terranova, Christopher, Khan, Fatima, Martinez-Ledesma, Juan, Gay, Jason, Gao, Guang, Mullinax, Robert A., Khor, Tin, Feng, Ningping, Lin, Yu-Hsi, Wu, Chia-Chin, Reyes, Claudia, Peng, Qian, Robinson, Frederick, Inoue, Akira, Kochat, Veena, Liu, Chang-Gong, Asara, John M., Moran, Cesar, Muller, Florian, Wang, Jing, Fang, Bingliang, Papadimitrakopoulou, Vali, Wistuba, Ignacio I., Rai, Kunal, Marszalek, Joseph, and Futreal, P. Andrew

Published
2018
Full Text
View/download PDF

5. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

Author

Hah, Hun J., Zhao, Mei, Pickering, Curtis R., Frederick, Mitchell J., Andrews, Genevieve A., Jasser, Samar A., Fooshee, David R., Milas, Zvonimir L., Galer, Chad, Sano, Daisuke, William, William N., Jr, Kim, Edward, Heymach, John, Byers, Lauren A., Papadimitrakopoulou, Vali, and Myers, Jeffrey N.

Published
2014
Full Text
View/download PDF

16. Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma.

Author

Goepfert, Ryan P., Lewin, Jan S., Barrow, Martha P., Fuller, C. David, Lai, Stephen Y., Song, Juhee, Hobbs, Brian P., Gunn, G. Brandon, Beadle, Beth M., Rosenthal, David I., Garden, Adam S., Kies, Merrill S., Papadimitrakopoulou, Vali A., Schwartz, David L., and Hutcheson, Katherine A.

Abstract

Objectives/hypothesis: To determine the factors associated with longitudinal patient-reported dysphagia as measured by the MD Anderson Dysphagia Inventory (MDADI) in locoregionally advanced oropharyngeal carcinoma (OPC) survivors treated with split-field intensity modulated radiotherapy (IMRT).Study Design: Retrospective patient analysis.Methods: A retrospective analysis combined data from three single-institution clinical trials for stage III/IV head and neck carcinoma. According to trial protocols, patients had prospectively collected MDADI at baseline, 6, 12, and 24 months after treatment. OPC patients with baseline and at least one post-treatment MDADI were included. Longitudinal analysis was completed with multivariate linear mixed effects modeling.Results: There were 116 patients who met inclusion criteria. Mean baseline MDADI composite was 88.3, dropping to 73.8 at 6 months, and rising to 78.6 and 83.3 by 12 and 24 months, respectively (compared to baseline, all P < .0001). Tumor stage and smoking status were significant predictors of longitudinal MDADI composite scores. Patients with T1, T2, and T3 tumors had 15.9 (P = .0001), 10.9 (P = .0049), and 7.5 (P = .0615), respectively, higher mean MDADI composite than those with T4 tumors, and current smokers had a 9.4 (P = .0007) lower mean MDADI composite than never smokers.Conclusions: Patients report clinically meaningful dysphagia early after split-field IMRT for locoregionally advanced OPC that remains apparent 6 months after treatment. MDADI scores recover slowly thereafter, but remain depressed at 24 months compared to baseline. Higher tumor stage and smoking status are important markers of patient-reported function through the course of treatment, suggesting these are important groups for heightened surveillance and more intensive interventions to optimize swallowing outcomes.Level Of Evidence: 4 Laryngoscope, 127:842-848, 2017. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

18. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Author

Shin, Dong M., Khuri, Fadlo R., Glisson, Bonnie S., Ginsberg, Lawrence, Papadimitrakopoulou, Vali M., Clayman, Gary, Lee, J. Jack, Ang, K. Kian, Lippman, Scott M., Hong, Waun Ki, Shin, D M, Khuri, F R, Glisson, B S, Ginsberg, L, Papadimitrakopoulou, V M, Clayman, G, Lee, J J, Ang, K K, Lippman, S M, and Hong, W K

Published
2001
Full Text
View/download PDF

20. Frequent inactivation of p16INK4a in oral premalignant lesions.

Author

Papadimitrakopoulou, Vali, Izzo, Julie, Lippman, Scott M, Lee, Jin Soo, Fan, You Hong, Clayman, Gary, Ro, Jay Y, Hittelman, Walter N, Lotan, Reuben, Hong, Waun K, and Mao, Li

Subjects
*HEAD & neck cancer, *IMMUNOHISTOCHEMISTRY, *CARCINOGENESIS, *SQUAMOUS cell carcinoma
Abstract

Head and neck carcinogenesis is believed to be a multistep process, whereby genetic events accumulate in the carcinogen-exposed field at risk, resulting in distinct phenotypic premalignant changes that eventually evolve into invasive cancer. Frequent loss of heterozygosity (LOH) at the chromosome 9p21 region and inactivation of p16INK4a by different mechanisms have been described in head and neck squamous cell carcinoma (HNSCC). Recently, we reported that loss of 9p21 is also frequent in oral premalignant lesions. To investigate potential inactivation of p16INK4a in these premalignant lesions, we analysed 74 biopsies from 36 patients by immunohistochemistry (IHC) for expression of the p16 protein. Loss of p16 expression was found in 28 (38%) of the lesion biopsies from 17 patients (47%). LOH at the D9s171, a marker in the 9p21 region, was observed in 19 lesion biopsies from 12 cases and correlated with absence of p16 by IHC in 11 (92%) of the 12 comparable cases and 15 (79%) of 19 lesion biopsies. By direct sequencing of ten lesion biopsies from ten individuals with LOH at D9s171 for p16INK4a exon 2, one non-sense mutation at codon 88 (GGA→TGA) was identified. Our data suggest that inactivation of p16INK4a may play an important role in early head and neck cancer development. [ABSTRACT FROM AUTHOR]

Published
1997
Full Text
View/download PDF

22. Combined-modality therapy in paranasal sinus cancer.

Author

Papadimitrakopoulou, Vali A. and Hong, Waun K.

Abstract

Presents the response to an article in the July/August 1999 issue of `The Cancer Journal from Scientific American' on use of combined-modality therapy in paranasal sinus cancer. Effectiveness; Purpose of intra-arterial chemotherapy; Patient response rate; Difficulty of comparing all types of head and neck squamous cell cancers.

Published
1999

23. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: Long-term follow-up.

Author

Papadimitrakopoulou, Vali A. and Hong, Waun K.

Subjects
*ISOTRETINOIN, *ORAL cancer, *CHEMOPREVENTION, *THERAPEUTICS
Abstract

Presents a study that compares the effectiveness of low-dose isotretinoin versus beta-carotene in preventing oral carcinogenesis. Median follow-up study of a 1993 randomized maintenance chemoprevention trial in oral premalignancy; Malignant transformation of advanced dysplastic oral premalignant lesions to invasive cancer.

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results